Extracorporeal circulation without bleeding.
A newly created antibody to the active site of Factor XIIa protects against clotting of extracorporeal bypass circuitry without bleeding risk in vivo, obviating the need for heparin (Larsson et al., this issue).
Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Alvin H
AH
Schmaier
D000906:Antibodies / Q000627:therapeutic use; D005112:Extracorporeal Circulation / Q000009:adverse effects*; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D013927:Thrombosis / Q000188:drug therapy
D000906:Antibodies; D006493:Heparin